B-ALL Clinical Trial
Official title:
IIT2017-05-MERIN-BLINHMCT: Blinatumomab Plus HLA-Mismatched Cellular Therapy (HMCT) for Relapsed/Refractory CD19+ ALL
Single center Phase 1 dose escalation trial of the combination of standard-of-care blinatumomab plus Haplo-Mismatched Cellular Therapy (HMCT). HMCT refers to the infusion of donor peripheral blood mononuclear cells collected via pheresis from a haploidentical family member - the procedure is analogous to giving a donor lymphocyte infusion outside of the setting of an allogeneic stem cell transplant; also known as 'microtransplantation'. The HMCT is an unselected mix of lymphocytes and leukocytes, but the product dose escalation will be done based on the T cell content. Ten recipients are planned. Each subject will be administered one infusion of HMCT during the first cycle of blinatumomab and two infusions during cycle two of blinatumomab; the CD3+ cell dose of the HMCT infusion is governed by dose escalation / de-escalation following a Bayesian method.
This single center, phase 1 study will examine the safety, side effects, and effectiveness of combining the investigational use of Haplo-Mismatched Cellular Therapy (HMCT) in combination with blinatumomab. Investigators plan to give HMCT starting on day 15, after the initial CRS caused by blinatumomab has resolved. The investigational treatment will start with 1% of the typical HMCT dose (10e6 CD3+ cells/kg) and will employ a modified dose escalation design as an additional safety measure. The primary end points will be DLT of the combination of blinatumomab and HMCT. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04088890 -
Autologous CD22 CAR T Cells in Adults w/ Recurrent or Refractory B Cell Malignancies
|
Phase 1 | |
Recruiting |
NCT04546906 -
Safety and Efficacy Study of CD22 CAR-T Cells for Relapsed or Refractory Acute Lymphoblastic Leukemia
|
N/A | |
Recruiting |
NCT04546893 -
Safety and Efficacy Study of SL1904B CAR-T Cells for Relapsed or Refractory B-Cell Acute Lymphocyte Leukemia
|
N/A | |
Active, not recruiting |
NCT01209286 -
Study of the BiTE® Blinatumomab (MT103) in Adult Patients With Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (ALL)
|
Phase 2 | |
Withdrawn |
NCT05571540 -
Anti-CD19 Universal CAR-T Cells for r/r CD19+ B-ALL
|
Phase 1/Phase 2 | |
Completed |
NCT01290120 -
Chemotherapy Plus Rituximab Combination for Adult Lymphoblastic Leukemia (B-ALL) and Burkitt's Non-Hodgkin Lymphoma
|
Phase 2 | |
Recruiting |
NCT04781634 -
a Clinical Research of CD19 and CD22 Targeted Prime CAR-T Cell in Relapsed/Refractory B-ALL
|
Phase 1/Phase 2 | |
Recruiting |
NCT03448393 -
CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies
|
Phase 1 | |
Recruiting |
NCT05350787 -
Evaluate the Safety, Efficacy and Pharmacokinetics of ThisCART19A in Patients With R/R B-ALL
|
Phase 1 | |
Recruiting |
NCT05350852 -
Evaluate the Safety, Efficacy and Pharmacokinetics of ThisCART19A in Patients With MRD+ B-ALL
|
Phase 1 | |
Recruiting |
NCT05621291 -
A Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-cell Recovery to Guide Management Following Chimeric Antigen Receptor T-cell (CART) Induced Remission in Children and Young Adults With B Lineage Acute Lymphoblastic Leu...
|
N/A | |
Active, not recruiting |
NCT04318678 -
CD123-Directed Autologous T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML)
|
Phase 1 | |
Active, not recruiting |
NCT04499573 -
Bispecific CD19/CD22 CAR-T for Treatment of Children and Young Adults With r/r B-ALL
|
Phase 1/Phase 2 | |
Recruiting |
NCT04512716 -
Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma
|
Early Phase 1 | |
Recruiting |
NCT05639179 -
Novel Anti-CD19 Universal CAR-T Cells for r/r CD19+ B-ALL
|
Phase 1/Phase 2 | |
Recruiting |
NCT04792593 -
Senl-h19 CAR-T Cell Injection in the Treatment of Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
|
N/A | |
Recruiting |
NCT05442515 -
CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT02328014 -
Acalabrutinib (ACP-196) in Combination With ACP-319, for Treatment of B-Cell Malignancies
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT02315612 -
Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies
|
Phase 1 |